



## Europass Curriculum Vitae



### Personal information

First name/ Surname **Federico Massa**

Work Address Largo Paolo Daneo 3, 16132, Genoa, Italy

Telephone(s) +39 0105557040

E-mail fedemassa88@gmail.com; federico.massa@unige.it

Nationality Italian

Date of birth November 6<sup>th</sup> 1988

Gender M

Occupation **Research fellow at the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINO GMI), University of Genoa, Genoa, Italy - disciplinary scientific area MED/26 – Neurology**

**Consultant Neurologist  
IRCCS Policlinico San Martino, Genoa (Italy)**

**Resume** I am a specialist in Neurology, graduated with honors, and earned a Ph.D. in Clinical and Experimental Neuroscience in May 2023. I have obtained the National Scientific Qualification as Associate Professor in the Italian education system for the disciplinary field Neurology. Currently, I serve as a Research Fellow at the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Sciences (DINOEMI) of the University of Genoa and as a Consultant Neurologist at the IRCCS Policlinico San Martino (Genoa, Italy). Since the early years of my training, I have been deeply engaged in the management of patients with neurodegenerative diseases, particularly dementia, movement disorders, and rare neuroinflammatory conditions, including autoimmune encephalitis. My research spans over 90 publications in international peer-reviewed journals and several monographs in book chapters, with more than 10 as the first author. I have developed specific expertise in molecular imaging and fluid biomarkers for diagnostic and prognostic purposes, contributing to key Italian research groups and international consortia advancing these fields. With a strong commitment to European healthcare and research collaboration, I actively contribute to the European Academy of Neurology (EAN) panels on cognitive and motor disorders, as well as high cortical functions. I hold the Certificate of Fellowship of the European Board of Neurology (FEBN) and currently serve as the Guideline Representative for the Dementia and Cognitive Disorders Panel of the EAN, playing a pivotal role in shaping and implementing clinical guidelines in this domain. I am an organized, proactive professional with a strong ability to work in multidisciplinary teams while fostering empathetic, clear, and responsible communication with patients. My skill set includes designing and executing research projects, conducting comprehensive data analyses, and critically evaluating findings. Passionate and dedicated, I efficiently manage multiple tasks while ensuring high-quality outcomes and effectively presenting experimental data to diverse audiences.

### Education and training

|  |  |
|--|--|
| Dates  | 14 <sup>th</sup> March 2025  |
| Title of qualification awarded                                 | National Scientific qualification as associate professor in the Italian higher education system, in the call 2023/2025 (Ministerial Decree n. 1796/2023) for the disciplinary field of 06/D6 - Neurology.                    |
| Name and type of organisation providing certification          | Italian Ministry of University and Research (MUR)  |
| Dates  | May 2023   |
| Title of qualification awarded                                 | PhD in Clinical and Experimental Neuroscience (XXXV cycle)   |
| Thesis title   | Harmonization and validation of liquid and imaging biomarkers in neurodegenerative diseases and autoimmune encephalitis (supervisors Prof. F. Nobili, Prof. M. Pardini; external reviewers Prof. GB. Frisoni, Prof. M. Otto) |
| Name and type of organisation providing education and training | Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa   |
| Dates  | Dec 10 <sup>th</sup> 2019  |
| Title of qualification awarded                                 | Specialist degree in Neurology (points 50/50 cum laude)  |
| Thesis title   | Reciprocal incremental value of 18F-FDG-PET and CSF biomarkers in MCI patients suspected for Alzheimer's disease and inconclusive first biomarker (supervisor Prof. F. Nobili)   |
| Name and type of organisation providing education and training | Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa   |
| Dates  | Jul 29 <sup>th</sup> 2013  |
| Title of qualification awarded                                 | Master's degree in medicine and surgery (points 110/110 cum laude)   |
| Thesis title   | Hippocampus, temporal associative fibers and memory in Multiple Sclerosis (supervisor: Prof. G. Mancardi)  |
| Name and type of organisation providing education and training | University of Genoa  |

## Certifications

Dates Mar 14<sup>th</sup> 2025 – Mar 14<sup>th</sup> 20237

National Scientific qualification as **associate professor** in the Italian higher education system, in the call 2023/2025 (Ministerial Decree n. 1796/2023) for the disciplinary field of 06/D6 - Neurology (Academic Recruitment Field 06/D - Medical specialities, according to the national classification).

Dates June 2025

EAN Certificate: Certified **Advocate for Neurology and Brain Health**

Dates June 2021

**Certificate of Fellowship of the European Board of Neurology (FEBN)** (13th UEMS-European Board of Neurology-European academy of Neurology (UEMS-EBN-EAN) examination, 13<sup>o</sup> ed., June 2021)

## Clinical experience

Dates Dec 11<sup>th</sup>, 2019 – Ongoing

Occupation Neurologist

Main activities and responsibilities Clinical activity at the Center for Cognitive Disorders and Dementia, with diagnosis and clinical management of patients with cognitive disorders and parkinsonisms, and the Neuroimmunology Outpatient Clinic, with diagnosis and clinical management of patients with autoimmune encephalitis. Consultant neurologist in the inpatient Neurology and Stroke units.

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa; IRCCS Policlinico San Martino Hospital, Genoa, Italy

Dates Dec 10<sup>th</sup>, 2014 – Dec 10<sup>th</sup>, 2019

Occupation Training Neurologist

Main activities and responsibilities Residency program in Neurology with in particular clinical activity at the Center for Cognitive Disorders and Dementia, with diagnosis and clinical management of patients with cognitive disorders and Parkinsonisms, the Neuroimmunology Outpatient Clinic, with diagnosis and clinical management of patients with autoimmune encephalitis, and Neurology inpatient and stroke unit

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa; IRCCS Policlinico San Martino Hospital, Genoa, Italy

## Research experience

Dates July 2024 – ongoing

Occupation Researcher, member of the Steering committee

Research project European Inter-Societal Consensus diagnostic workflow: revised-version integrating blood-based and other innovative biomarkers

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Dates Oct 1<sup>st</sup>, 2023– ongoing

Occupation Principal investigator

Research project Integrating biomarkers for Mild Behavioral Impairment: a multifaceted analysis of neurodegenerative, psychiatric, and neurosurgical etiologies

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Funding/Grant 40,000 Euros

Dates March 1st, 2023– ongoing  
Occupation Researcher  
Research project MNESYS (PE0000006) – A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022)  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Dates March 1st, 2023– ongoing  
Occupation Researcher  
Research project Artificial intelligence of imaging and clinical neurological data for predictive, preventive and personalized (P3) medicine (NeuroArtP3) for Alzheimer's Disease - NET-2018-12366666-2-AD  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Dates Nov 1<sup>st</sup>, 2022 – Feb 28<sup>th</sup>, 2023  
Occupation Fellowship for collaboration on research activities  
Research project Evaluation of the diagnostic and prognostic role of fluid and imaging biomarkers in neurodegenerative diseases and autoimmune encephalitis  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa.

Dates Sep 1st, 2022– ongoing  
Occupation Researcher  
Research project Validation of the Italian consensus recommendations for the biomarker-based etiological diagnosis of neurocognitive disorders (ValiCo)  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Dates Nov 1st, 2023– ongoing  
Occupation Researcher  
Research project Validation of the European consensus for the biomarker-based diagnosis of neurocognitive disorders: an investigator-initiated sponsored study (EURO-ValiCo)  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Dates Sep 1st, 2020 – February 2024  
Occupation Researcher, member of the Executive Board  
Research project Recommendations for the Biomarker-Based Diagnosis of Dementia: a European Inter-Societal Delphi Consensus  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Dates Nov 1st, 2020 – ongoing  
Occupation Researcher - referent of the Policlinico San Martino IRCCS for the IVN Dementias, IVN Parkinson's and IVN Motor neuron disease Biochemistry task  
Research project Virtual National Institutes (IVN) of Dementias, Parkinson's disease, motor neuron disease and multiple sclerosis of the IRCCS Network of Neurohealth and Neurorehabilitation  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa; IRCCS Policlinico San Martino Hospital, Genoa, Italy

Dates January 1st, 2015 – ongoing

Occupation Sub-investigator (SI) in clinical trials or observation studies

Research projects

- A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis
- CBAF312A2304: Multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312.
- A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis (PPMS).
- A Phase III, multicenter, randomized, parallel-group, double blinded, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis (ORATORIO)
- A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 with a Long-Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer's Disease. (Protocol No. MK-8931-017-13) (also known as SCH 900931, P07738)
- A Phase 3 Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease.
- Strategic project promoted by the Italian Medicines Agency (AIFA), INTERCEPTOR project, on early diagnosis of the prodromal stage of Alzheimer disease. the progression from mild cognitive impairment (MCI) to dementia: the role of biomarkers in early interception of patients candidate for prescription of future disease-modifying drugs

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa; IRCCS Policlinico San Martino Hospital, Genoa, Italy

#### Laboratory experience

Dates Dec 1<sup>st</sup> 2019 - ongoing

Occupation Researcher

Main activity Analysis and test reporting of CSF biomarkers of neurodegenerative disorders with automatic CLEIA method (150 patients/year)

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa; IRCCS Policlinico San Martino Hospital, Genoa, Italy

Dates Jan 13<sup>st</sup> 2021 – Jul 30<sup>th</sup> 2021

Occupation Research fellow

Main activity Fellowship at the experimental laboratory of the German Center for Neurodegenerative disease (DZNE, Universitätsklinikum, Ulm, Germany; Prof. Otto M) focused on the CSF analysis and synaptic biomarkers of neurodegenerative disorders.

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa

Dates Jan 1<sup>st</sup> 2017 – Nov 30<sup>th</sup> 2019

Occupation Researcher

Main activity Analysis and test reporting of CSF biomarkers of neurodegenerative disorders with enzyme-linked immunosorbent assay (ELISA) from (60 patients/year)

Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa; IRCCS Policlinico San Martino Hospital, Genoa, Italy

Dates July 2017

Occupation Research fellow

Main activity Fellowship at the Experimental neurology laboratory (University of Perugia, 'Santa Maria della Misericordia' Hospital, Perugia, Italy; Prof. Parnetti L) focused on the CSF analysis and diagnosis of neurodegenerative disorders

### **Consortia or study groups**

Dates Feb 2025 – ongoing  
Occupation Scientific Committee  
Study group SINDEM 4 Juniors  
SIN-DEM Associazione Autonoma Aderente alla SIN per le demenze

Dates Feb 2023 – ongoing  
Occupation Directive board  
Study group Triregional study group SINDEM Piemonte-Liguria-Valle d'Aosta  
SIN-DEM Associazione Autonoma Aderente alla SIN per le demenze

Dates June, 2023 – ongoing  
Occupation Panel Member - Resident and Research Fellow Section  
Guideline representative for the Dementia and cognitive disorders panel (May 2024 – ongoing)  
Scientific panels European Academy of Neurology – Dementia and cognitive disorders – with specific activities:  
- Panel e-learning material revision and updating (March 2024)  
European Academy of Neurology – Movement disorders and cognitive disorders  
European Academy of Neurology – Higher cortical functions

Dates Jan, 2024 – ongoing  
Occupation Member  
Consortium European Dementia with Lewy bodies (E-DLB) consortium

Dates Sep, 2022 – ongoing  
Occupation Member  
Consortium European Alzheimer's disease consortium (EADC)

Dates June, 2024 – ongoing  
Occupation Member of the Steering Committee  
Study group Associazione Italiana Medicina Nucleare (AIMN) - Gruppo di Studio NEUROLOGIA

### **Academic experience**

Dates Sep 2023 – ongoing  
Occupation Lecturer  
Course (academic year) Bachelor's degree in physiotherapy (University of Genoa) - Adult Neuropsychology  
Academic year 2023/2024 (20 hours), year 2024/2025 (20 hours)  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa.

Dates Sep 2022  
Occupation Lecturer  
Course (academic year) Summer School of the Neuroscience Doctoral Program, University of Genoa: New diagnostic and therapeutic perspectives in Lewy body diseases, from prodromal to full-blown stages (3 hours).  
Academic year 2021/2022, Session II, September 2022  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOEMI), University of Genoa.

Dates June 2021  
Occupation Lecturer  
Course (academic year) Second-level Master's program in "Cognitive Disorders and Dementias" at the University of Genoa, :  
Liquor and plasma biomarkers in dementias (4 hours).  
Academic year 2020/2021  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health  
(DINOGLMI), University of Genoa.

Dates Sep 2023 – ongoing  
Occupation Co-supervisor of Specialization Degree Theses  
Course (academic year) Bachelor's degree in medicine and surgery at the University of Genoa  
Supervisors  
Prof. F. Nobili: academic year 2016/17 (n=1), 2018-19 (n=1), 2020-21 (n=2), 2021-22 (n=1),  
Prof. M. Pardini: 2022-23 (n=1), 2024-25 (m=1)  
Prof. A Schenone (2023-24) (n=1)  
Name and address of employer Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health  
(DINOGLMI), University of Genoa.

### Peer-reviewed publications

1. Nobili F, Westman E, Kogan RV, Pereira JB, **Massa F**, Grazzini M, Meles SK, Leenders KL. Clinical utility and research frontiers of neuroimaging in movement disorders. *Q J Nucl Med Mol Imaging*. 2017 Dec;61(4):372-385 (IF=2.368)
2. Arnaldi D, De Carli F, Famà F, Brugnolo A, Girtler N, Picco A, Pardini M, Accardo J, Proietti L, **Massa F**, Bauckneht M, Morbelli S, Sambuceti G, Nobili F. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. *Mov Disord*. 2017 Dec;32(12):1738-1747 (IF=7.072)
3. Origone P, Gotta F, Lamp M, Trevisan L, Geroldi A, Massucco D, Grazzini M, **Massa F**, Ticconi F, Bauckneht M, Marchese R, Abbruzzese G, Bellone E, Mandich P. Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier. *Cerebellum Ataxias*. 2018 Mar 14;5:7 (IS=1.89)
4. Bauckneht M, Chincarini A, Piva R, Arnaldi D, Girtler N, **Massa F**, Pardini M, Grazzini M, Efeeturk H, Pagani M, Sambuceti G, Nobili F, Morbelli S. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD). *Alzheimers Res Ther*. 2018 Apr 3;10(1):35 (IF=5.015)
5. Girtler N, Grazzini M, **Massa F**, Meli R, Arnaldi D. Getting the high school diploma with only one hemisphere: a case report. *Neurol Sci*. 2018 Dec;39(12):2203-2206 (IF=2.285)
6. De Carli F, Nobili F, Pagani M, Bauckneht M, **Massa F**, Grazzini M, Jonsson C, Peira E, Morbelli S, Arnaldi D; Alzheimer's Disease Neuroimaging Initiative. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. *Eur J Nucl Med Mol Imaging*. 2019 Feb;46(2):334-347 (IF=7.704)
7. Benedetti L, Briani C, Beronio A, **Massa F**, Giorli E, Sani C, Delia P, Artioli S, Sormani MP, Mannironi A, Tartaglione A, Mancardi GL. Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study. *J Peripher Nerv Syst*. 2018 Nov 13 (IF=2.55)
8. **Massa F**, Franciotta D, Gastaldi M, Mancardi GL, Benedetti L. N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders. *Schizophr Res* 2018 Dec;202:406-407 (IF=3.958)
9. **Massa F**, Arnaldi D, De Cesari F, Girtler N, Brugnolo A, Grazzini M, Bauckneht M, Meli R, Morbelli S, Pardini M, Sambuceti G, De Carli F, Tiraboschi P, Nobili F. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. *Neurobiol Aging*. 2018 Dec 13;76:9-17 (IF=4.347)
10. Brugnolo A, De Carli F, Pagani M, Morbelli S, Jonsson C, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzegza A, van Berckel BNM, Ossenkoppele R, Didic M, Guedj E, Arnaldi D, **Massa F**, Grazzini M, Pardini M, Mecocci P, Dottorini ME, Bauckneht M, Sambuceti G, Nobili F. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease. *J Alzheimers Dis*. 2019;68(1):383-394 (IF=3.909)

11. Lapucci C, Boffa G, **Massa F**, Franciotta D, Castelletti L, Uccelli A, Morbelli S, Nobili F, Benedetti L, Roccatagliata L. Could Arterial Spin Labeling perfusion imaging uncover the invisible in NMDAR encephalitis? *Eur J Neurology*. 2019 Oct;26(10):e86-e87 (IF 4.387)
12. **Massa F**, Meli R, Morbelli S, Nobili F, Pardini M. Editorial Commentary - Serum NfL rate of change in Alzheimer's disease: potentials applications and notes of caution. *Ann Transl Med*. 2019;7(Suppl 3):S133 (IF 3.689)
13. Benedetti L, Garnero M, Demichelis C, Grandis M, Briani C, Beltramini S, Bellucci M, Prada V, **Massa F**, Gastaldi M, Schenone A, Franciotta D. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years. *J Neuroimmunol*. 2019 Oct 15;337:577081 (IF 2.832)
14. Prada V, **Massa F**, Salerno A, Fregosi D, Beronio A, Serrati C, Mannironi A, Mancardi G, Schenone A, Benedetti L. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barré syndrome long-term outcome: a retrospective study. *Neurol Sci*. 2020 Feb;41(2):321-327 (IF 2.484)
15. **Massa F**, Farotti L, Eusebi P, Capello E, Dottorini ME, Tranfaglia C, Bauckneht M, Morbelli S, Nobili F, Parnetti L. Reciprocal incremental value of 18F-FDG-PET and cerebrospinal fluid biomarkers in Mild Cognitive Impairment patients suspected for Alzheimer's disease and inconclusive first biomarker. *J Alzheimers Dis*. 2019;72(4):1193-1207 (IF 3.909)
16. Gastaldi M, Mariotto S, Giannoccaro MP, Iorio R, Zoccarato M, Nosadini M, Benedetti L, Casagrande S, Di Filippo M, Valeriani M, Ricci S, Bova S, Arbasino C, Mauri M, Versino M, Vigeveno F, Papetti L, Romoli M, Lapucci C, **Massa F**, Sartori S, Zuliani L, Barilaro A, De Gaspari P, Spagni G, Evoli A, Liguori R, Ferrari S, Marchioni E, Giometto B, Massacesi L, Franciotta D. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. *Eur J Neurol*. 2020; 27:633-643 (IF 4.387)
17. Orso B, Mattei C, Arnaldi D, **Massa F**, Serafini G, Plantone D, Doglione E, Grafman J, Nobili F, Pardini M. Clinical and MRI predictors of conversion from Mild Behavioural Impairment to dementia. *Am J Geriatr Psychiatry*. 2020;28:755-76 (IF 3.488)
18. Arnaldi D, Donniaquo A, Mattioli P, **Massa F**, Grazzini M, Meli R, Filippi L, Grisanti S, Famà F, Terzaghi M, Girtler N, Brugnolo A, Doglione E, Pardini M, Villani F, Nobili F. Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study. *J Alzheimers Dis*. 2020;74(3):865-874 (IF 3.909)
19. Arnaldi D, Chincarini A, De Carli F, Famà F, Girtler N, Brugnolo A, Pardini M, **Massa F**, Meli R, Schenone C, Bauckneht M, Morbelli S, Nobili F. The fate of patients with REM sleep behavior disorder and Mild Cognitive Impairment. *Sleep Medicine*. 2021;79:205-210 (IF 3.456)
20. **Massa F**, Zuppa A, Pesce G, Demichelis C, Bergamaschi M, Garnero M, Briani C, Ferrari S, Schenone A, Benedetti L. Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. *J Neurol Sci*. 2020 Jun 15;413:116777 (IF 2.65)
21. Rosa G, Giannotti C, Martella L, **Massa F**, Serafini G, Pardini M, Nobili F, Monacelli F & Disease Management Team on Dementia of the IRCCS Ospedale Policlinico San Martino (Genoa, I). Brain Aging, Cardiovascular Diseases, Mixed Dementia, and Frailty in the Oldest Old: From Brain Phenotype to Clinical Expression. *J Alzheimers Dis*. 2020;75(4):1083-1103 (IF 3.909)
22. **Massa F**, Meli R, Grazzini M, Famà F, De Carli F, Filippi L, Arnaldi A, Pardini M, Morbelli S, Nobili F. Utility of quantitative EEG in early Lewy body disease. *Park Rel Dis*. 2020;75:70-75 (IF 3.926)
23. Orso B, Arnaldi D, Famà F, Girtler N, Brugnolo A, Doglione E, Filippi L, **Massa F**, Peira E, Bauckneht M, Morbelli S, Nobili F, Pardini M. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease. *Cortex*. 2020 Sep;130:401-412 (IF 4.009)
24. **Massa F**, Grisanti S, Brugnolo A, Doglione E, Orso B, Morbelli S, Bauckneht M, Origone P, Filippi L, Arnaldi D, De Carli F, Pardini M, Pagani M, Nobili F, Girtler N. The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease. *Neurobiol Aging*. 2020; 96: 117-127 (IF 4.347)
25. Morbelli S, Arnaldi D, Cella E, Raffa S, Donegani MI, Capitanio S, **Massa F**, Miceli A, Filippi L, Chincarini A, Nobili F. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools. *EJNMMI Res*. 2020 Nov 7;10(1):137 (IF 2.64)

26. Arnaldi D, Famà F, Girtler N, Brugnolo A, Pardini M, Mattioli P, Meli R, **Massa F**, Orso B, Sormani MP, Donegani MI, Bauckneht M, Morbelli S, Nobili F. REMeDio: a proof-of-concept neuroprotection study for prodromal synucleinopathies. *Eur J Neurol*. 2021 Apr;28(4):1210-1217 (IF 4.516)
27. Brugnolo A, Girtler N, Doglione E, Orso B, **Massa F**, Donegani MI, Bauckneht M, Morbelli S, Arnaldi D, Nobili F, Pardini M. Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). *Diagnostics*. 2021; 11(1):108 (IF 3.110)
28. Mattioli P, Pardini M, Famà F, Girtler N, Brugnolo A, Orso B, Meli R, Filippi L, Grisanti S, **Massa F**, Bauckneht M, Miceli A, Terzaghi M, Morbelli S, Nobili F, Arnaldi D. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. *Eur J Nucl Med Mol Imaging*. 2021 Aug;48(9):2834-2845. doi: 10.1007/s00259-021-05205-6 (IF 7.08).
29. **Massa F**, Filippi L, Benedetti L, Morbelli S, Nobili F. FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis. *Clin Nucl Med*. 2021 Jun 1;46(6):e327-e328. (IF 6.622)
30. Donegani MI, Miceli A, Pardini M, Bauckneht M, Chiola S, Pennone M, Marini C, **Massa F**, Raffa S, Ferrarazzo G, Arnaldi D, Sambuceti G, Nobili F, Morbelli S. Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection. *Biomedicine*. 2021 Mar 12;9(3):287 (IF 4.717)
31. Orso B, Arnaldi D, Girtler N, Brugnolo A, Doglione E, Mattioli P, Biassoni E, Fancellu R, **Massa F**, Bauckneht M, Chiola S, Morbelli S, Nobili F, Pardini M. Dopaminergic and Serotonergic Degeneration and Cortical [18F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. *Mov Disord*. 2021 May 22; 36: 2293-2302 (IF 8.679)
32. Grisanti SG, Franciotta D, Garnero M, Zuppa A, **Massa F**, Mobilia EM, Pesce G, Schenone A, Benedetti L. A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection. *J Neuroimmunology*. 2021 Aug 15;357:577605 (IF 3.125)
33. Demichelis C, Grisanti S, **Massa F**, Serrati C, Beronio A, Mannironi A, Mobilia E, Briani C, Schenone A, Benedetti L. Abnormal sweating and "skin flushing" as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature. *J Neurol Sci*. 2021 Sep 15;428:117589 (IF 3.181)
34. Gómez de San José N, **Massa F**, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. *J Neural Transm*. 2021(IF=4.348)
35. Arnaldi D, Mattioli P, Famà F, Girtler N, Brugnolo A, Pardini M, Donniaquio A, **Massa F**, Orso B, Raffa S, Bauckneht M, Morbelli S, Nobili F. Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy. *Mov Disord* 2022 Jan;37(1):52-61 (IF 10.338)
36. Orso B, Famà F, Giorgetti L, Mattioli P, Donniaquio A, Girtler N, Brugnolo A, **Massa F**, Peira E, Pardini M, Morbelli S, Nobili F, Arnaldi D. Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson's Disease. *Neurol Sci*. 2022 Apr;43(4):2531-2536 (IF 3.307)
37. **Massa F**, Chincarini A, Bauckneht M, Raffa S, Peira E, Arnaldi A, Pardini M, Pagani M, Orso B, Donegani MI, Brugnolo A, Biassoni E, Mattioli P, Girtler N, Guerra UP, Morbelli S, Nobili F. Added value of semi-quantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2022; 49:1263–1274 (IF=9.236)
38. Orso B, Lorenzini L, Arnaldi D, Girtler N, Brugnolo A, Doglione E, Mattioli P, Biassoni E, **Massa F**, Peira E, Bauckneht M, Donegani MI, Morbelli S, Nobili F, Pardini M. The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer's Disease and Frontotemporal Dementia. *Biomedicine*. 2022; 10(3):544 (IF 6.081)
39. Girtler N, Chincarini A, Brugnolo A, Doglione E, Orso B, Morbelli S, **Massa F**, Peira E, Biassoni E, Donniaquio A, Grisanti S, Pardini M, Arnaldi D, Nobili F. The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort. *J Alzheimers Dis*. 2022;87(2):887-899 (IF 4.472)
40. Grisanti SG, Garbarino S, Barisione E, Aloè T, Grosso M, Schenone C, Pardini M, Biassoni E, Zaottini F, Picasso R, Morbelli S, Campi C, Pesce G, **Massa F**, Girtler N, Battaglini D, Cabona C, Bassetti M, Uccelli A, Schenone A, Piana M, Benedetti L. Neurological long-COVID in the outpatient clinic: Two subtypes, two courses. *J Neurol Sci*. Volume 439, 2022 (IF=3.181)

41. **Massa F**, Halbgebauer S, Barba L, Oeckl P, Gómez de San José N, Bauckneht M, Lanfranchi F, Vigo T, Arnaldi D, Pardini M, Morbelli S, Chincarini A, Barthel H, Otto M, Nobili F. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data. *Neurobiol Aging*. 2022 Sep;117:212-221 (IF=5.133)
42. Barba L, Halbgebauer S, Paolini Paoletti F, Bellomo G, Abu-Rumeileh S, Steinacker P, **Massa F**, Parnetti L, Otto M. Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease. *Int J Mol Sci*. 2022; 23(13):6922 (IF=6.208)
43. Bellucci M, Germano F, Grisanti S, Castellano C, Tazza F, Mobilia EM, Visigalli D, Novi G, **Massa F**, Rossi S, Durando P, Cabona C, Schenone A, Franciotta D, Benedetti L. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome (GBS) Following an Antecedent Para-infectious COVID-19-related GBS. *Front Immunol*. 2022 Jul 18;13:894872 (IF=8.786)
44. **Massa F**, Franciotta D, Grisanti S, Roccatagliata L, Morbelli S, Beltramini S, Uccelli A, Schenone A, Benedetti L. Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments. *Neurol Sci*. 2022 43, 6441–6447 (IF=3.830)
45. Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, Steinacker P, **Massa F**, Gaetani L, Parnetti L, Otto M. Cerebrospinal fluid  $\beta$ -synuclein as a synaptic biomarker for preclinical Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2022 Aug 9:jnnp-2022-329124. doi: 10.1136/jnnp-2022-329124 (IF=13.654)
46. Orso B, Arnaldi D, Peira E, Famà F, Giorgetti L, Girtler N, Brugnolo A, Mattioli P, Biassoni E, Donniaquio A, **Massa F**, Bauckneht M, Miceli A, Morbelli S, Nobili F, Pardini M. The Role of Monoaminergic Tones and Brain Metabolism in Cognition in de novo Parkinson's Disease. *J Parkinsons Dis*. 2022;12(6):1945-1955 (IF=5.520)
47. Matricardi S, Casciato S, Bozzetti S, Mariotto S, Stabile A, Freri E, Deleo F, Sartori S, Nosadini M, Pappalardo I, Meletti S, Giovannini G, Zucchi E, Di Bonaventura C, Di Gennaro G, Ferrari S, Zuliani L, Zoccarato M, Vogrig A, Lattanzi S, Michelucci R, Gambardella A, Ferlazzo E, Fusco L, Granata T, Villani F; Immune Epilepsies Study Group of the Italian League Against Epilepsy\*. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy. *J Neurol Neurosurg Psychiatry*. 2022 Jul 25:jnnp-2022-329195 (IF 13.654); \* as member of the study group
48. Festari C, **Massa F**, Cotta Ramusino M, Gandolfo F, Nicolosi V, S Orini, Aarsland D, Agosta F, Babiloni C, Boada M, Borroni B, Cappa S, Dubois B, Frederiksen KS, Frölich L, Garibotto V, Georges J, Haliassos A, Hansson O, Jessen F, Kamondi A, Kessels RPC, Morbelli S, O'Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Ritchie CW, Scheltens P, van der Flier WM, Vandenbulcke M, Vanninen R, Verhey FRJ, Vernooij MW, Yousry T, Nobili F, Frisoni GB. European consensus for the diagnosis of MCI and mild dementia: preparatory phase. *Alzheimer's and dementia*. 2022 Oct 9 (IF 16.655)
49. Mattioli P, Pardini M, Girtler N, Brugnolo A, Orso B, Donniaquio A, Calizzano F, Mancini R, **Massa F**, Terzaghi M, Bauckneht M, Morbelli S, Sambuceti G, Nobili F, Arnaldi D. Cognitive and brain metabolism profiles of mild cognitive impairment in prodromal synucleinopathy. *J Alzheimers Dis*. 2022;90(1):433-444 (IF=4.160)
50. Ruscitti F, Origone P, Rosti G, Trevisan L, Marchese R, Brugnolo A, **Massa F**, Castellini P, Mandich P. A case of Huntington disease-like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era. *Clin case rep*. 2022; 10:e06308 (IS 0.57)
51. Mattioli P, Orso B, Liguori C, Famà F, Giorgetti L, Donniaquio A, **Massa F**, Giberti A, Vázquez García D, Meles SK, Leenders KL, Placidi F, Spanetta M, Chiaravallotti A, Camedda R, Schillaci O, Izzi F, Mercuri NB, Pardini M, Bauckneht M, Morbelli S, Nobili F, Arnaldi D. Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder. *Mov Disord*. 2022 Oct 3 (IF=9.698)
52. Ferraro PM, Gualco L, Costagli M, Schiavi S, Ponzano M, Signori A, **Massa F**, Pardini M, Castellan L, Levrero F, Zacà D, Piredda GF, Hilbert T, Kober T, Roccatagliata L. Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements. *Phys Med*. 2022 Nov 8;103:166-174 (IF=3.119)
53. Lanfranchi F, Arnaldi D, Miceli A, Mattioli P, D'Amico F, Raffa S, Donegani MI, Chiola S, **Massa F**, Pardini M, Di Raimondo T, Sambuceti G, Bauckneht M, Nobili F, Morbelli S. Different z-score cut-offs for Striatal Binding Ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB). *EJNMMI*. 2022 Dec 6. (IF=9.111)

54. Grisanti SG\*, **Massa F\***, Chincarini A, Pretta S, Rissotto R, Serrati C, Monacelli F, Serafini G, Calcagno P, Brugnolo A, Pardini M, Nobili F, Girtler N; Dementia Disease Management Team. Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnesic Mild Cognitive Impairment. *J Alzheimers Dis.* 2023 Mar 14 (IF=4.160) **\*equally contributing as first authors**
55. Biassoni E, Kreshpa W, **Massa F**, D'Amico F, Bauckneht M, Arnaldi D, Pardini M, Orso B, Girtler N, Brugnolo A, Morbelli S, Tinazzi M, Nobili F, Mattioli P. Right posterior hypometabolism in Pisa syndrome of Parkinson's disease: A key to explain body schema perception deficit? *Parkinsonism Relat Disord.* 2023 Mar 17;110:105371 (IF=4.402)
56. Orso B, Mattioli P, Yoon EJ, Kim YK, Kim H, Shin JH, Kim R, Liguori C, Famà F, Donniaquio A, **Massa F**, García DV, Meles SK, Leenders KL, Chiaravalloti A, Pardini M, Bauckneht M, Morbelli S, Nobili F, Lee JY, Arnaldi D. Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort. *Neurol Sci.* 2023 Sep;44(9):3161-3168 (IF=3.830)
57. Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, Oeckl P, Steinacker P, **Massa F**, Parnetti L, Otto M. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease. *Neurology.* 2023 Jul 4;101(1):e50-e62 (IF=9.900)
58. Foschi M, Abu-Rumeileh S, **Massa F**, Cordano C, Abdelhak A. Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases. *Front Neurol.* 2023 Jul 11; 14:1239750 (IF=3.400)
59. Babiloni C, Lopez S, Noce G, Ferri R, Panerai S, Catania V, Soricelli A, Salvatore M, Nobili F, Arnaldi D, Famà F, **Massa F**, Buttinelli C, Giubilei F, Stocchi F, Vacca L, Marizzoni M, D'Antonio F, Bruno G, De Lena C, Güntekin B, Yıldırım E, Hanoğlu L, Yener G, Yerlikaya D, Taylor JP, Schumacher J, McKeith I, Bonanni L, Pantano P, Piervincenzi C, Petsas N, Frisoni GB, Del Percio C, Carducci F. Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to Alzheimer's disease. *Cereb Cortex.* 2023 Aug 23:bhad300 (IF=4.861)
60. Brugnolo A, Orso B, Girtler N, Ferraro PM, Arnaldi D, Mattioli P, **Massa F**, Famà F, Argenti L, Biffa G, Morganti W, Buonopane S, Uccelli A, Morbelli S, Pardini M. Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages. *Cortex.* 2024 Feb;171:413-422 (IF=3.600)
61. Oltra J, Habich A, Schwarz CG, Nedelska Z, Przybelski SA, Inguanzo A, Diaz-Galvan P, Lowe VJ, Oppedal K, Gonzalez MC, Philippi N, Blanc F, Barkhof F, Lemstra AW, Hort J, Padovani A, Rektorova I, Bonanni L, Massa F, Kramberger MG, Taylor JP, Snaedal JG, Walker Z, Antonini A, Dierks T, Segura B, Junque C, Westman E, Boeve BF, Aarsland D, Kantarci K, Ferreira D. Sex differences in brain atrophy in dementia with Lewy bodies. *Alzheimers Dement.* 2023 Dec 22. doi: 10.1002/alz.13571. Epub ahead of print. PMID: 38131463. (IF=14.000)
62. **Massa F**, Martinuzzo C, Gómez de San José N, Pelagotti V, Kreshpa W, Abu-Rumeileh S, Barba L, Mattioli P, Orso B, Brugnolo A, Girtler N, Vigo T, Arnaldi D, Serrati C, Uccelli A, Morbelli S, Chincarini A, Otto M, Pardini M. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease. *J Neurol.* 2023 Dec 29. doi: 10.1007/s00415-023-12154-7. PMID: 38157030 (IF=6.000).
63. **Massa F**, Vigo T, Bellucci M, Giunti D, Emanuela MM, Visigalli D, Capodivento G, Cerne D, Assini A, Boni S, Rizzi D, Narciso E, Grisanti GS, Coco E, Uccelli A, Schenone A, Franciotta D, Benedetti L. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome. *Neurol Sci.* 2024 Mar;45(3):849-859. doi: 10.1007/s10072-023-07279-6. Epub 2024 Jan 3. PMID: 38169013 (IF=3.300).
64. Cerne D, Losa M, Mattioli P, Lechiara A, Rebella G, Roccatagliata L, Arnaldi D, Schenone A, Morbelli S, Benedetti L, **Massa F**. Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword. *J Neuroimmunol.* 2024 Feb 15;387:578291. doi: 10.1016/j.jneuroim.2024.578291. Epub 2024 Jan 14. PMID: 38237526 (IF=3.300)
65. Sofia L, **Massa F**, Pardini M, Arnaldi D, Bauckneht M, Morbelli S. Alzheimer's disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era. *Eur J Nucl Med Mol Imaging.* 2024 Jan 29. doi: 10.1007/s00259-024-06619-8. PMID: 38285205. (IF=9.100).

66. Cotta Ramusino M, **Massa F**, Festari C, Gandolfo F, Nicolosi V, Orini S, Nobili F, Frisoni GB, Morbelli S, Garibotto V; European Inter-Societal Consensus on the Biomarker-Based Diagnosis of Dementia. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review. *Eur J Nucl Med Mol Imaging*. 2024 Feb 15. doi: 10.1007/s00259-024-06631-y. PMID: 38355740. (IF=9.100)
67. Frisoni GB, Festari C, **Massa F**, Cotta Ramusino M, Orini S, Aarsland D, Agosta F, Babiloni C, Borroni B, Cappa SF, Frederiksen KS, Froelich L, Garibotto V, Haliassos A, Jessen F, Kamondi A, Kessels RP, Morbelli SD, O'Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Vandenbulcke M, Vanninen R, Verhey F, Vernooij MW, Yousry T, Boada Rovira M, Dubois B, Georges J, Hansson O, Ritchie CW, Scheltens P, van der Flier WM, Nobili F. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. *Lancet Neurol*. 2024 Mar;23(3):302-312. doi: 10.1016/S1474-4422(23)00447-7. PMID: 38365381 (IF=48.000).
68. Babiloni C, Jakhar D, Tucci F, Del Percio C, Lopez S, Soricelli A, Salvatore M, Ferri R, Catania V, **Massa F**, Arnaldi D, Famà F, Güntekin B, Yener G, Stocchi F, Vacca L, Marizzoni M, Giubilei F, Yıldırım E, Hanoğlu L, Hünerli D, Frisoni GB, Noce G. Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer's disease mild cognitive impairment progression at a 6-month follow-up. *Neurobiol Aging*. 2024 Feb 1;137:19-37. Doi: 10.1016/j.neurobiolaging.2024.01.013. PMID: 38402780 (IF=4.200).
69. Arnaldi D, Mattioli P, Raffa S, Pardini M, Massa F, Iranzo A, Perissinotti A, Niñerola-Baizán A, Gaig C, Serradell M, Muñoz-Lopetegui A, Mayà G, Liguori C, Fernandes M, Placidi F, Chiaravalloti A, Šonka K, Dušek P, Zogala D, Trnka J, Boeve BF, Miyagawa T, Lowe VJ, Miyamoto T, Miyamoto M, Puligheddu M, Figorilli M, Serra A, Hu MT, Klein JC, Bes F, Kunz D, Cochen De Cock V, de Verbizier D, Plazzi G, Antelmi E, Terzaghi M, Bossert I, Kulcsárová K, Martino A, Giuliani A, Pagani M, Nobili F, Morbelli S; International REM Sleep Behavior Disorder Study Group. Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy. *Ann Neurol*. 2024 Mar 11. doi: 10.1002/ana.26902. Epub ahead of print. PMID: 38466158. (IF=11.274).
70. Sofia L, Massa F, Raffa S, Pardini M, Arnaldi D, Bauckneht M, Morbelli S. Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer's disease (AD) mimickers. *Eur J Nucl Med Mol Imaging*. 2024 Mar 14. doi: 10.1007/s00259-024-06676-z. Epub ahead of print. PMID: 38480553. (IF=9.100).
71. Sanvito F, Pichiecchio A, Paoletti M, Rebella G, Resaz M, Benedetti L, Massa F, Morbelli S, Caverzasi E, Asteggiano C, Businaro P, Masciocchi S, Castellan L, Franciotta D, Gastaldi M, Roccatagliata L. Autoimmune encephalitis: what the radiologist needs to know. *Neuroradiology*. 2024 Mar 20. doi: 10.1007/s00234-024-03318-x. Epub ahead of print. PMID: 38507081
72. Mattioli P, Grisanti S, **Massa F**, Morbelli S, Boni S, Beronio A, Rebella G, Roccatagliata L, Nobili L, Franciotta D, Micalizzi E, Nobili F, Arnaldi D, Villani F, Benedetti L. Ma2 antibody-associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory. *Epileptic Disord*. 2024 Apr 15. doi: 10.1002/epd2.20225. Epub ahead of print. PMID: 38619369
73. Barba L, Abu-Rumeileh S, Barthel H, **Massa F**, Foschi M, Bellomo G, Gaetani L, Thal DR, Parnetti L, Otto M. Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease. *Brain*. 2024 Oct 3;147(10):3325-3343. doi: 10.1093/brain/awae203. PMID: 38991041
74. **Massa F**, Villain N, Cotta Ramusino M, Frisoni GB. Clinical versus biomarker-based diagnosis of neurocognitive disorders - Authors' reply. *Lancet Neurol*. 2024 Aug;23(8):766-767. doi: 10.1016/S1474-4422(24)00275-8. PMID: 39030035
75. Kreshpa W, Raffa S, Girtler N, Brugnolo A, Mattioli P, Orso B, Calizzano F, Arnaldi D, Peira E, Chincarini A, Tagliafico L, Monacelli F, Calcagno P, Serafini G, Gotta F, Mandich P, Pretta S, Del Sette M, Sofia L, Sambuceti G, Morbelli S, Schenone A, **Massa F\***, Pardini M\*; Dementia Disease Management Team of the IRCCS Ospedale Policlinico San Martino, Genoa. Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer's Disease: Clues from [18F]FDG PET Voxel-Wise Analysis. *J Alzheimers Dis*. 2024;101(2):475-485. doi: 10.3233/JAD-240430. PMID: 39240639. \*equally contributing as last authors
76. Rebella G, Cerne D, Benedetti L, Morbelli S, Resaz M, Uccelli A, Castellan L, Villani F, Peira E, **Massa F<sup>✉</sup>**, Roccatagliata L. FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis. *Q J Nucl Med Mol Imaging*. 2024 Sep 12. doi: 10.23736/S1824-4785.24.03583-0. Epub ahead of print. PMID: 39264242

77. Hamedani M, Caneva S, Mancardi GL, Ali PA, Fiaschi P, **Massa F**, Schenone A, Pardini M. Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia. *J Alzheimers Dis*. 2024 Sep 11. doi: 10.3233/JAD-240559. Epub ahead of print. PMID: 39269840.
78. Raffa S, Sofia L, Girtler N, Pardini M, Arnaldi D, Orso B, Donegani MI, D'Amico F, Lanfranchi F, Rovera G, **Massa F**, Mattioli P, Sambuceti G, Bauckneht M, Morbelli S. Metabolic and dopaminergic correlates of intellectual enrichment in de-novo Parkinson's disease patients. *Q J Nucl Med Mol Imaging*. 2024 Sep 23. doi: 10.23736/S1824-4785.24.03585-4. Epub ahead of print. PMID: 39311478
79. Orso B, Mattioli P, Yoon EJ, Kim YK, Kim H, Shin JH, Kim R, Famà F, Brugnolo A, **Massa F**, Chiaravalloti A, Fernandes M, Spanetta M, Placidi F, Pardini M, Bauckneht M, Morbelli S, Lee JY, Liguori C, Arnaldi D. Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study. *NPJ Parkinsons Dis*. 2024 Oct 25;10(1):200. doi: 10.1038/s41531-024-00813-z. PMID: 39448609.
80. Cerne D, **Massa F**, Mora M, et al. Anti-LGI1 encephalitis and Langerhans cell histiocytosis: Two associated entities? A case report. *Heliyon*. 2024;10(20):e39586. Published 2024 Oct 18. doi:10.1016/j.heliyon.2024.e39586
81. Righi D, Manco C, Pardini M, Stufano A, Schino V, Pelagotti V, **Massa F**, Stefano N, Plantone D. Investigating interleukin-8 in Alzheimer's disease: A comprehensive review. *J Alzheimers Dis*. 2024 Nov 18:13872877241298973. doi: 10.1177/13872877241298973. Epub ahead of print. PMID: 39558604.
82. Ferraro PM, Filippi L, Ponzano M, Signori A, Orso B, **Massa F**, Arnaldi D, Caneva S, Argenti L, Losa M, Lombardo L, Mattioli P, Costagli M, Gualco L, Pulze M, Plantone D, Brugnolo A, Girtler N, Diociai A, Garbarino S, Villani F, Sormani MP, Uccelli A, Roccatagliata L, Pardini M; Alzheimer's Disease Neuroimaging Initiative. Clinical and biological underpinnings of longitudinal atrophy pattern progression in Alzheimer's disease. *J Alzheimers Dis*. 2024 Nov 25:13872877241299843. doi: 10.1177/13872877241299843. Epub ahead of print.
83. Lombardi G, Pancani S, Manca R, Mitolo M, Baiardi S, **Massa F**, Coppola L, Franzese M, Nicolai E, Guerini FR, Mancuso R, Agliardi C, Agostini S, Pardini M, Virgili G, Sorbi S, Parchi P, Nacmias B, Venneri A. Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer's Disease: A Review and Meta-Analysis. *Int J Mol Sci*. 2024 Nov 30;25(23):12916. doi: 10.3390/ijms252312916.
84. Del Percio C, Lizio R, Lopez S, Noce G, Carpi M, Jakhar D, Soricelli A, Salvatore M, Yener G, Güntekin B, Massa F, Arnaldi D, Famà F, Pardini M, Ferri R, Carducci F, Lanuzza B, Stocchi F, Vacca L, Coletti M, Marizzoni M, Taylor JP, Hanoğlu L, Helvacı Yılmaz N, Kıyı İ, Özbek-İşbitiren Y, D'Anselmo A, Bonanni L, Biundo R, D'Antonio F, Bruno G, Antonini A, Giubilei F, Farotti L, Parnetti L, Frisoni GB, Babiloni C (2025). Resting-State EEG Alpha Rhythms Are Related to CSF Tau Biomarkers in Prodromal Alzheimer's Disease. *International Journal of Molecular Sciences*, 26(1), 356. <https://doi.org/10.3390/ijms26010356>
85. Del Percio C, Lizio R, Lopez S, Noce G, Jakhar D, Carpi M, Bölükbaş B, Soricelli A, Salvatore M, Güntekin B, Yener G, Massa F, Arnaldi D, Famà F, Pardini M, Ferri R, Salerno M, Lanuzza B, Stocchi F, Vacca L, Coletti C, Marizzoni M, Taylor JP, Hanoğlu L, Yılmaz NH, Kıyı İ, Özbek-İşbitiren Y, Frisoni GB, Cuoco S, Barone P, D'Anselmo A, Bonanni L, Biundo R, D'Antonio F, Bruno G, Giubilei F, De Pandis F, Rotondo R, Antonini A, Babiloni C. Resting-state electroencephalographic rhythms depend on sex in patients with dementia due to Parkinson's and Lewy Body diseases: An exploratory study. *Neurobiol Dis*. 2025 Jan 22:106807. doi: 10.1016/j.nbd.2025.106807.
86. Kiersnowski OC, Mattioli P, Argenti L, Avanzino L, Calizzano F, Diociai A, Falcitano L, Liu C, Losa M, Massa F, Morbelli S, Orso B, Pelosin E, Raffa S, Pardini M, Arnaldi D, Roccatagliata L, Costagli M. Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies. *Sci Rep*. 2025 Feb 4;15(1):4186. doi: 10.1038/s41598-024-83593-z. PMID: 39905067; PMCID: PMC11794440.

87. Salamone EM, Carpi M, Noce G, Percio CD, Lopez S, Lizio R, Jakhar D, Eldellaa A, Isaza VH, Bölükbaş B, Soricelli A, Salvatore M, Güntekin B, Yener G, Massa F, Arnaldi D, Famà F, Pardini M, Ferri R, Salerno M, Lanuzza B, Stocchi F, Vacca L, Coletti C, Marizzoni M, Taylor JP, Hanoğlu L, Yılmaz NH, Kıyı İ, Kula H, Frisoni GB, Cuoco S, Barone P, D'Anselmo A, Bonanni L, Biundo R, D'Antonio F, Bruno G, Giubilei F, Antonini A, Babiloni C. Abnormal electroencephalographic rhythms from quiet wakefulness to light sleep in Alzheimer's disease patients with mild cognitive impairment. *Clin Neurophysiol.* 2025 Jan 31;171:164-181. doi: 10.1016/j.clinph.2025.01.012. Epub ahead of print..
88. Plantone D, Pardini M, Manco C, Righi D, Ali PA, Arnaldi D, Pelagotti V, Massa F, d'Alessandro M, Bargagli E, De Stefano N. CSF IL-6, GDF-15, GFAP and NFL levels in early Alzheimer disease: a pilot study. *Ther Adv Neurol Disord.* 2025 Feb 19;18:17562864251314773. doi: 10.1177/17562864251314773.
89. Losa M, Garbarino S, Cirone A, Argenti L, Lombardo L, Calizzano F, Girtler N, Brugnolo A, Mattioli P, Bauckneht M, Raffa S, Sambuceti G, Canosa A, Caneva S, Piana M, Bozzo G, Roccatagliata L, Serafini G, Uccelli A, Gotta F, Origone P, Mandich P, Massa F, Morbelli S, Arnaldi D, Orso B, Pardini M. Clinical and metabolic profiles in behavioural frontotemporal dementia: Impact of age at onset. *Cortex.* 2025 Feb 11;185:84-95. doi: 10.1016/j.cortex.2025.01.011.
90. Arnaldi D, Mattioli P, Orso B, **Massa F**, Pardini M, Morbelli S, Nobili F, Figorilli M, Casaglia E, Mulas M, Terzagli M, Capriglia E, Malomo G, Solbiati M, Antelmi E, Pizza F, Biscarini F, Puligheddu M and Plazzi G. (2025), The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon. *Eur J Neurol*, 32: e70169. <https://doi.org/10.1111/ene.70169>
91. S Lopez, C Del Percio, R Lizio, G Noce, D Jakhar, A Soricelli, M Salvatore, B Güntekin, G Yener, **F Massa**, D Arnaldi, F Famà, M Pardini, R Ferri, F Carducci, B Lanuzza, F Stocchi, L Vacca, C Coletti, M Marizzoni, J P Taylor, L Hanoğlu, N Helvacı Yılmaz, İ Kıyı, Y Özbek-İşbitiren, A D'Anselmo, L Bonanni, R Biundo, F D'Antonio, G Bruno, A Antonini, F Giubilei, S Cuoco, P Barone, G B Frisoni, R Rotondo, F De Pandis, C Babiloni. The compensatory effect of education as revealed by resting-state electroencephalographic alpha rhythms in patients with dementia due to Parkinson's disease: findings from an exploratory study. *Geroscience* 2025 (accepted)
92. Riello M, Moroni M, Bovo S, Ragni F, Buganza M, Di Giacomo R, Chierici M, Gios L, Pardini M, Massa F, Dallabona M, Vanzetta E, Campi C, Piana M, Garbarino S, Marengo M, Osmani V, Jurman G, Uccelli A, Giometto Bnd NeuroArtP3 Network. Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease. *Front. Aging Neurosci.* 2025. 17:1565006. doi: 10.3389/fnagi.2025.1565006
93. Tagliafico L, Bogliacino E, Raffa S, Girtler N, Brugnolo A, Mattioli P, Arnaldi D, Marozzi V, Giacomini G, Nencioni A, Serafini G, Nozza P, Gotta F, Mandich P, Pretta S, Gandoglia I, Del Sette M, Sofia L, Hamedani M, Roccatagliata L, Losa M, Biffa G, Argenti L, Castellini P, Lombardo L, Lorenzini L, Serrati C, Pulze M, Sambuceti G, Bozzo G, Morbelli SD, Schenone A, **Massa F**, Pelagotti V, Kreshpa W, Monacelli F, Orso B, Pardini M; Disease Management Team on Dementia of the IRCCS Ospedale Policlinico San Martino. How can we define a brain health chart? A narrative review and a proposal. *J Alzheimers Dis.* 2025 May 25:13872877251343233. doi: 10.1177/13872877251343233. Epub ahead of print.

#### Book chapters

1. Van Veen R, Talavera Martinez L, Kogan RV, Meles SK, Mudali D, Roerdink JBTM, **Massa F**, Grazzini M, Obeso JA, Rodríguez-Oroz MC, Leenders KL, Renken RJ, de Vries JGG, Biehl M. Machine Learning Based Analysis of FDG-PET Image Data for the Diagnosis of Neurodegenerative Diseases. *Frontiers in Artificial Intelligence and Applications. Volume 310: Applications of Intelligent Systems*, 280 – 289. doi: 10.3233/978-1-61499-929-4-280.
2. Capitanio S, Bauckneht M, Arnaldi D, **Massa F**, Meli R, Ceriani V, Nobili F, Morbelli S. 18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease. In: Fraioli F. (eds) *PET/CT in Brain Disorders. Clinicians' Guides to Radionuclide Hybrid Imaging (2019)*. Springer, Cham
3. **Massa F**, Bauckneht M, Peira E, Lapucci C, Picco A, Capitanio S, Arnaldi D, Roccatagliata L, Chincarini A, Nobili F. Neuroimaging Findings in Mild Cognitive Impairment. In: Dierckx R.A.J.O., Otte A., de Vries E.F.J., van Waarde A., Leenders K.L. (eds) *PET and SPECT in Neurology (2021)*. Springer, Cham.
4. **Massa F**, Bauckneht M, Capitanio S, Grazzini M, Meli R, Filippi L, Ceriani S, Grisanti S, Morbelli S, Nobili F. Capitolo 3 – L'imaging molecolare nella diagnosi delle malattie neurodegenerative del sistema nervoso. In: Gallosti (cur.) *Demenze. Consigli Clinici.* (p. 59-96). Neuroscience 2000. CLEUP, 2021.

5. **Massa F**, Arnaldi D, Balma M, Bauckneht M, Chincarini A, Ferraro PM, Grazzini M, Lapucci C, Meli R, Morbelli S, Pardini M, Peira E, Raffa S, Roccatagliata L, Nobili F. Chapter 5 - Sex differences in neuroimaging biomarkers in healthy subjects and dementia. In: Ferretti MT, Schumacher Dimech A, Santuccioni Chadha A. Sex and Gender Differences in Alzheimer's Disease - 1st Edition (p.125-162). Academic Press, 2021.
6. **Massa F**, Morbelli S. Case 4: Parkinson's Disease with Onset as Mild Cognitive Impairment (MCI). In: Varrone A, Morbelli S, Garibotto V. Clinical nuclear medicine in neurology: an atlas of challenging cases -1st Edition (pp. 19-24). Springer Cham 2022

**Editorial activity** Associate Editor – Journal of Alzheimer's Disease (Jan 1st 2020 –Dec 31st 2020; Jan 1st 2023-Dec 31st 2024) (IF 4.00)  
Co-Topic Editor – Frontiers in Neurology (Mar 2022 – Sep 2023) (IF 3.552)

### Refereeing Activity

**Indexed Journals** Scientific Reports (Jan 2019) (IF 4.011)  
Brain Imaging and Behavior (Jun 2019) (IF 3.418)  
Frontiers in Neuroscience (Oct 2019) (IF 3.566)  
Journal of Alzheimer's Disease (Mar 2020, May 2020, Jul 2020, Mar 2021, Jun 2021, Dec 2023) (IF 3.517)  
Parkinsonism & Related Disorders (Sep 2020, Dec 2022) (IF 4.402)  
European Journal of Nuclear Medicine and Molecular Imaging (Dec 2020, Oct 2022) (IF 9.11)  
European Journal of Neurology (Jan 2022, Aug 2022) (IF 6.288)  
Journal of Neurological the Sciences (Nov 2021, Mar 2022, Feb 2024, Mar 2024) (IF 3.08)  
NeuroImage: Clinical (Mar 2022) (IF 4.881)  
Journal of Integrative Neuroscience (Apr 2022) (IF 2.117)  
Neurobiology of Aging (Oct 2022) (IF 5.133)  
Alzheimer's Research and Therapy (Dec 2024) (IF 9.000)  
Journal of Neurology, Neurosurgery, and Psychiatry (Mar 2025) (IF 8.8)

**Congress abstracts** Alzheimer's Association International Conference(AAIC)® 2024, July 28-Aug1 2024, Philadelphia, US

**Invited speaker activity** "L'esame del liquor". Il cervello che cambia 7. Genoa, November 11th, 2017.  
"L'esame liquorale nelle malattie neurodegenerative". Congresso riunito SIGG-AIP. Le nuove frontiere nella cura della demenza: diagnosi precoce, cure palliative, biotestamento e fine vita. Rapallo (Genoa), May 18th-19th, 2018.  
"Neuroimmunologia Clinica: casi clinici con sessione video". New frontiers in Neuroimmunology. Genoa, January 25th, 2019.  
"Fluid biomarkers in dementia". Course in Neurodegenerative disorders. Padova, May 29th, 2019.  
"Aggiornamento in tema di biomarcatori liquorali nella diagnosi delle malattie neurodegenerative". Il cervello che cambia 9 - Disordini cognitivi e demenze: recenti avanzamenti e frontiere di ricerca, Genova, November 9th, 2019.  
"Biomarcatori liquorali: caratteristiche delle demenze pre-senili" - Il cervello che cambia 11 – Le demenze pre-senili: sono diverse? - Genoa, November 6th 2021.  
"Tavola rotonda: consensus europea su come orientarsi nel labirinto dei biomarcatori". XV national congress of Associazione Italiana Medicina Nucleare (AIMN) – Rimini, May 12-15th 2022.  
"Guida alla scelta dei biomarcatori per la diagnosi eziologica dei disturbi neurocognitivi: un consensus intersocietario europeo". 22° national congress of Associazione Italiana Psicogeriatra (AIP) – Florence, May 23-25th 2022.  
"Introduzione all'esame del liquido cefalorachidiano" – Basic course of Nuclear Medicine - Pesaro 29 settembre – october 1st 2022.  
"Nuovi biomarcatori liquorali emergono" - Il cervello che cambia 12 – Giovani virgulti crescono al CDCD del policlinico San Martino e dintorni - Genoa, November 2022

“Linee guida europee sull'uso dei bio-marker nelle Demenze” – Advanced course of Nuclear Medicine - Pesaro 28-30th September 2023

“Markers liquorali ed ematici: a che punto siamo, quali prospettive, quali problemi” – Advanced course of Nuclear Medicine - Pesaro 28-30th September 2023

“Exploring metabolic correlates of cerebrospinal fluid proteins in prodromal Alzheimer’s Disease”. European Alzheimer’s disease consortium (EADC) meeting – Genoa 12-13th October 2023

“Dalla analisi visiva a quella semiquantitativa con piattaforma DO-Lab Research Edition” – Scuola di Neuro-imaging molecolare – Prato 1st-12nd December 2023

“Le nuove raccomandazioni intersocietarie per la diagnosi eziologica nel decadimento cognitivo lieve - “Riunione triregionale SINDEM Piemonte - Liguria - Valle d’Aosta – Torino 16th December 2023

“Prognosi ed esito cognitivo” - Encefaliti autoimmuni ed epilessie autoimmuni: due entità a confronto - Genoa, 18-19th April 2024

“Biomarkers fluidi per AD: dove siamo e dove stiamo andando” - Scientific Exchange Meeting – pathfinder” – Optimize treatment strategies: when and how to integrate amyloid-targeted therapies in early symptomatic Alzheimer’s disease management” – Rome, 23-24th May 2024

“European recommendations for biomarker-based diagnosis of neurocognitive disorders” - Neuro24 Fórum de Neurologia e o Congresso Nacional da Sociedade Portuguesa de Neurocirurgia – Figueira da Foz (Portugal), June 6-8th, 2024.

“Cosa si aspettano i clinici dal medico-nucleare: consensus Europea sulla diagnosi etiologica dei disturbi cognitivi e motori”

“La fisiopatologia dei disturbi del movimento, cosa sappiamo e cosa non sappiamo: dalla anatomia patologica alla clinica, dalle sindromi alle malattie”

“La fisiopatologia delle demenze, cosa sappiamo e cosa non sappiamo: dalla anatomia patologica alla” – Basal course of Nuclear Medicine – Pesaro, September 26-28th 2024

“Case vignette: esemplificazione dell'uso clinico delle raccomandazioni in 6 casi clinici”. Evento formativo residenziale - Raccomandazioni Europee per l'uso dei biomarcatori nel processo diagnostico dei disturbi neurocognitivi allo stadio MCI - IRCCS Fatebenefratelli, Brescia, October 11th 2024

“Biomarcatori biologici plasmatici nella malattia di Alzheimer: quale futuro?”. Simposio – Malattia di Alzheimer: quando la biologia si allea con la clinica. Congresso Nazionale di Neurologia (SIN), Roma, November 10th, 2024

“Significato clinico ed interpretazione della PET amiloide nei disturbi cognitivi”

“Utilità dei dati clinici e neuropsicologici nell'interpretazione delle immagini PET”

Corso di “Neuroimaging funzionale nella pratica clinica”. Bolzano, November 15-16th 2024.

“Avanzamenti e prospettive dei biomarcatori fluidi nei disturbi cognitivi”. Riunione triregionale SINDEM Piemonte - Liguria - Valle d’Aosta – Genoa, November 30th, 2024

“Non-conventional CSF biomarkers in neurodegenerative disorders”. Memory Center Symposium, Hopitalux Universitaires Genève – Genève (CH), February 10th 2025

“DATSCAN in Dementia”. 39° Reuniao anual – Grupo de estudos de envecimiento cerebral e demencia - Aveiro (PT), 16-17th May 2025

“L'importanza della diagnosi precoce”. Corso: La cognitività prima della malattia: Potenziamento e Terapia – Genoa, May 24th 2025

**Scientific contributes in national/international congresses as presenting author – ORAL COMMUNICATIONS**

F. Massa, C. Lapucci, E. Giorli, M. Godani, S. Zupo, G. Cerruti, D. Siccardi, S. Boni, C. Serrati, G. Mancardi, L. Benedetti. The utility of molecular PCR assays to detect clonal rearrangement in immunoglobulin and t-cell receptor VDJ-region genes in CSF samples of suspected lymphoproliferative diseases. XLVII SIN congress. Venice, Oct 22-25th 2016.

F. Massa, C. Lapucci, E. Giorli, M. Godani, S. Zupo, G. Cerruti, D. Siccardi, S. Boni, C. Serrati, G. Mancardi, L. Benedetti. Clinical significance of clonal rearrangement detection through molecular PCR assays in suspicious lymphoproliferative diseases CSF samples. XLVIII SIN congress. Naples, Oct 14-17th 2017.

F. Massa, E. Capello, G.L., Mancardi, F. Nobili. CSF analysis in dementia: clinical utility and new perspectives. 7° Giornata dello specializzando in neurologia. Milan, May 15th 2018.

- F. Massa, D. Franciotta, M. Gastaldi, G. Mancardi, L. Benedetti. N-Methyl-D-Aspartate receptor antibody-related pathologies and pre-existent mental state disorders. XLIX SIN congress. Rome, oct 27-30th 2018.
- F. Massa, A. Chincarini, M. Bauckneht, S. Raffa, E. Peira, D. Arnaldi, M. Pardini, M. Pagani, B. Orso, I. Donegani, A. Brugnolo, E. Biassoni, P. Mattioli, N. Girtler, U.P. Guerra, S. Morbelli, F. Nobili. Accuracy of FDG-PET at the individual level in MCI-LB versus MCI-AD: A stepwise approach from visual to semi-quantitative analysis. 25° World congress of Neurology (WCN2021). Virtual, oct 3rd-7th 2021.
- F. Massa, M. Bauckneht, S. Raffa, B. Orso, D. Arnaldi, M. Pardini, M. Pagani, A. Brugnolo, N. Girtler, S. Morbelli, A. Chincarini, U.P. Guerra, F. Nobili. Accuracy of 18F-FDG PET at the individual level in MCI-LB versus MCI-AD. 7th Congress of the European Academy of Neurology, Virtual, Jun 19-22th 2021.
- F. Massa, A. Chincarini, B. Orso, P. Mattioli, S.G. Grisanti, A. Brugnolo, N. Girtler, S. Morbelli, M. Pardini, for the Dementia Disease Management Team of the IRCCS Ospedale Policlinico San Martino, Genoa. The metabolic correlates of apathy and unawareness of apathy differ in patients with amnesic mild cognitive impairment due to Alzheimer's disease. European Conference on Clinical Neuroimaging (ECCN) – 11th edition. Genoa, Mar 13-15th 2023
- F. Massa F, C. Martinuzzo, N. Gómez de San José, V. Pelagotti V, W. Kreshpa, S. Abu-Rumeileh, L. Barba, P. Mattioli, B. Orso, A. Brugnolo, N. Girtler, T. Vigo, D. Arnaldi, C. Serrati, A. Uccelli, S. Morbelli, A. Chincarini, M. Otto, M. Pardini M. Exploring cerebrospinal fluid NPTX2 changes and spatial associations with brain metabolism in the course of prodromal Alzheimer's disease. 18th International Conference on Alzheimer's & Parkinson's Diseases (ADPD24). Lisboa (Portugal). Mar 5-9th 2024.

**Scientific contributes in national/international congresses as presenting author – POSTER**

**F. Massa**, et al. Atypical systemic sclerosis-related myositis: report of a case. XLVI congresso SIN. Genova, 10-13 ottobre 2015.

**F. Massa**, et al. Reward perception in subjects with hyposmia: which relationship with the development of Parkinson's disease? XLVII congresso SIN. Venezia, 22-25 ottobre 2016.

**F. Massa**, et al. Ecologically-relevant isolated apathy as an early symptom of neurodegeneration. XLVII congresso SIN. Venezia, 22-25 ottobre 2016.

**F. Massa**, et al. The utility of molecular PCR assay to detect clonal rearrangement in immunoglobulin VDJ-region genes in CSF samples of suspected lymphoproliferative diseases. 57° congresso nazionale SNO. Napoli, 24-26 maggio 2017.

**F. Massa**, et al. Cognitive onset Parkinson's disease or prodromal DLB? XLVIII congresso SIN. Napoli, 14-17 ottobre 2017.

**F. Massa**, et al. Is The B-cell-activating factor a negative prognostic factor in Rituximab retreated anti-MAG polyneuropathy patients? XXVII AINI Congress. Trieste, 7-10 maggio 2018.

**F. Massa**, et al. Relative incremental value of 18F-FDG-PET and CSF biomarkers in suspected Alzheimer's disease. XLIX congresso SIN. Roma, 27-30 ottobre 2018.

**F. Massa**, et al. Brain metabolic correlates of word version of free and cued selective reminding test (FCRST) in prodromal AD. XLIX congresso SIN. Roma, 27-30 ottobre 2018.

**F. Massa**, et al. N-Methyl-D-Aspartate receptor antibody-related pathologies and pre-existent mental state disorders. XXVIII AINI Congress. Camogli, 6-9 maggio 2019.

**F. Massa**, et al. Relative incremental value of 18F-FDG-PET and CSF biomarkers in suspected Alzheimer's disease. 8° Giornata dello specializzando in neurologia. Milano, 11 giugno 2019.

**F. Massa**, et al. Cholinergic deficit in Parkinson's disease with cognitive onset is revealed by quantitative EEG. 50° congresso SIN. Bologna, 12-15 ottobre 2019.

**F. Massa**, et al. FDG-PET unveils the course of paraneoplastic cerebellar degeneration: a semiquantitative analysis. 51° congresso SIN. Virtuale, 28-30 novembre 2020.

**F. Massa**, et al. Brain metabolic correlates of process specific CSF biomarkers in MCI due to Alzheimer's disease. 8th Congress of the European Academy of Neurology, Wien (AT), 25-28 June 2022.

**F. Massa**, et al. European Inter-Societal Delphi Consensus for the biomarker-based etiological diagnosis of neurocognitive disorders in the mild stage. Alzheimer's Association International Conference® (2022). San Diego (CA, USA) and virtual. July 31 –August 4, 2022.

**F. Massa**, et al. Assessment of apathy by patients and its discrepancy with estimation by caregivers rely on different metabolic correlates in amnesic mild cognitive impairment due to Alzheimer's disease. 52° congresso SIN. Milano, 3-6 dicembre 2022.

**F. Massa**, et al. Apathy and unawareness of apathy differ in neural pathways in prodromal Alzheimer's disease: an FDG-PET study. 9th Congress of the European Academy of Neurology, Budapest (HU), July 1st-4th 2023.

**F. Massa**, et al. The difference in apathy estimates between the patient and caregiver predicts dementia in individuals with amnesic MCI. Alzheimer's Association International Conference® (2023). Amsterdam (The Netherlands). July 16 –20, 2023

**F. Massa**, et al. CSF NPTX2 dynamic changes and topographic relations with brain metabolism across MCI due to Alzheimer's Disease. 53° SIN Congress Naples 2023. October 21-24<sup>th</sup> 2023.

**F. Massa et al.** CSF synaptic proteins and monoaminergic systems in prodromal Alzheimer's disease: insights from [18F]FDG PET correlations 10th Congress of the European Academy of Neurology, Helsinki (HU), June 29<sup>th</sup>-July 2<sup>nd</sup> 2024.

**F. Massa et al.** Mapping monoaminergic system vulnerability in prodromal Alzheimer's disease: correlations with cerebrospinal fluid biomarkers and [18F]FDG-PET hypometabolism. RIN (Rete Italiana Neuroscienze) congress, Genoa, Nov 22<sup>nd</sup> 2024

**F. Massa et al.** Serotonergic receptor maps overlap with cortical metabolism changes and CSF NPTX2 in prodromal Alzheimer's disease .11th Congress of the European Academy of Neurology, Helsinki (HU), June 21<sup>st</sup>-June 24<sup>th</sup> 2025.

**Prizes and awards** **Best poster award** - '8° Giornata dello specializzando in neurologia' Milan 2019 with the contribution "Relative incremental value of 18F-FDG-PET and CSF biomarkers in suspected Alzheimer's disease".  
**Best poster award** and Travel grant "Progetto Giovani" – 53° SIN Congress Naples 2023 with the contribution " CSF NPTX2 dynamic changes and topographic relations with brain metabolism across MCI due to Alzheimer's Disease"  
**Best poster award** - RIN (Rete Italiana Neuroscienze) congress, Genoa, Nov 22<sup>nd</sup> 2024, with the contribution "Mapping monoaminergic system vulnerability in prodromal Alzheimer's disease: correlations with cerebrospinal fluid biomarkers and [18F]FDG-PET hypometabolism."  
Travel grant "Progetto Giovani" - XLVI Sin Congress Genoa 2015 with the contribution "Atypical systemic sclerosis-related myositis: report of a case."  
Travel grant "Progetto Giovani" - XLVII Sin Congress Venice 2016 with the contribution "The utility of molecular PCR assay to detect clonal rearrangement in immunoglobulin VDJ-region genes in CSF samples of suspected lymphoproliferative diseases."  
Travel grant "Progetto Giovani" - 57° SNO Congress Naples 2017 con il contributo dal titolo "The utility of molecular PCR assay to detect clonal rearrangement in immunoglobulin VDJ-region genes in CSF samples of suspected lymphoproliferative diseases."  
Travel grant "Progetto Giovani" - XLVIII SIN Congress Naples 2017 with the contribution "Clinical significance of clonal rearrangement detection through molecular PCR assays in suspicious lymphoproliferative diseases CSF samples"  
Travel Grant - XXVII AINI Congress Trieste 2018 with the contribution "Is The B-cell-activating factor a negative prognostic factor in Rituximab retreated anti-MAG polyneuropathy patients?".  
Travel grant "Progetto Giovani" - XLIX SIN Congress Rome 2018 with the contribution "N-methyl-D-aspartate receptor antibody-related pathologies and pre-existent mental state disorders".  
Travel Grant - XXVIII AINI Congress Camogli 2019 with the contribution "N-methyl-D-aspartate receptor antibody-related pathologies and pre-existent mental state disorders".  
Travel grant "Progetto Giovani" - 50° SIN Congress Bologna 2019 with the contribution "Cholinergic deficit in parkinson's disease with cognitive onset is revealed by quantitative EEG".  
Travel Grant - 8th European Academy of Neurology (EAN) Congress, Vienna 2022 with the contribution "Brain metabolic correlates of process-specific CSF biomarkers in MCI due to Alzheimer's disease  
Conference Fellowship per Alzheimer's Association International Conference® 2022 (AAIC), San Diego (CA, USA) and virtual, 2022, with the contribution "European Inter-Societal Delphi Consensus for the biomarker-based etiological diagnosis of neurocognitive disorders in the mild stage"  
Travel Grant - 9th European Academy of Neurology (EAN) Congress, Budapest 2023 with the contribution "Apathy and unawareness of apathy differ in neural pathways in prodromal Alzheimer's disease: an FDG-PET study".  
Travel Grant – 11th Congress of the European Academy of Neurology, Helsinki (FI) 2025 with the contribution "Serotonergic receptor maps overlap with cortical metabolism changes and CSF NPTX2 in prodromal Alzheimer's disease"

## Personal skills and competences

Use of statistical software for data analysis, including Graphpad Prism, R, and other widely adopted tools in clinical and research settings.

Advanced skills in creating impactful and professional presentations using Microsoft PowerPoint, tailored to both scientific audiences and broader professional contexts.

Expertise in using **Statistical Parametric Mapping (SPM)** software for the analysis and interpretation of Positron Emission Tomography (PET) imaging data, with a strong focus on neuroimaging applications in research and clinical practice.

Laboratory expertise in performing and interpreting immunoassays for research and diagnostic purposes, with a focus on proteins implicated in neurodegenerative diseases

Mother tongue(s) **Italian**

Other language(s) **English, French**

| Self-assessment<br><i>European level</i> (*) | Understanding |                 |         |                  | Speaking           |                 |                   |                 | Writing |                 |
|--|---------------|-----------------|---------|------------------|--------------------|-----------------|-------------------|-----------------|---------|-----------------|
|  | Listening     |                 | Reading |                  | Spoken interaction |                 | Spoken production |                 |         |                 |
| <b>English</b>                               | C1            | Proficient user | C1      | Proficient user  | C1                 | Proficient user | C1                | Proficient user | C1      | Proficient user |
| <b>French</b>                                | A1            | Basic user      | B1      | Independent user | A1                 | Basic user      | A1                | Basic user      | A1      | Basic user      |

(\*) [Common European Framework of Reference for Languages](#)

*I hereby grant my permission for my personal data to be used pursuant to the Italian law 196/2003, regarding the privacy of individuals*

*Sincerely,*

*Genoa, June 4th, 2025*